EUVIMEDEUVIMED entdecken
Crossref

Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials

Verena Staedtke, Kara Anstett iD, David Bedwell, Marco Giovannini, Kim Keeling, Robert Kesterson, YooRi Kim, Bruce Korf, André Leier, Miranda L McManus iD, Herb Sarnoff iD, Jeremie Vitte iD und 3 weitere

Clinical Trials · 2024

DOI: 10.1177/17407745231207970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2024. Verfasst von Verena Staedtke und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibromatosis 2, Neurofibromatoses, Neurilemmoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous successful gene-targeted therapies are arising for the treatment of a variety of rare diseases. At the same time, current treatment options for neurofibromatosis 1 and schwannomatosis are limited and do not directly address loss of gene/protein function. In addition, treatments have mostly focused on symptomatic tumors, but have failed to address multisystem involvement in these conditions. Gene-targeted therapies hold promise to address these limitations. However, despite intense interest over decades, multiple preclinical and clinical issues need to be resolved before they become a reality. The optimal approaches to gene-, mRNA-, or protein restoration and to delivery to the appropriate cell types remain elusive. Preclinical models that recapitulate manifestations of neurofibromatosis 1 and schwannomatosis need to be refined. The development of validated assays for measuring neurofibromin and merlin activity in animal and human tissues will be critical for early-stage trials, as will the selection of appropriate patients, based on their individual genotypes and risk/benefit balance. Once the safety of gene-targeted therapy for symptomatic tumors has been established, the possibility of addressing a wide range of symptoms, including non-tumor manifestations, should be explored. As preclinical efforts are underway, it will be essential to educate both clinicians and those affected by neurofibromatosis 1/schwannomatosis about the risks and benefits of gene-targeted therapy for these conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Neurofibromatosis 2NeurofibromatosesNeurilemmomaSkin NeoplasmsAnimalsHumans

Stichwörter der Autor:innen

Neurofibromatosis type 1bonebone mineral densityclinical trialsosteoporosis

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
  • Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles, Los Angeles, CA, USA.
  • Department of Cancer Precision Medicine, Pennington Biomedical Research Center, Baton Rouge, LA, USA.
  • Gilbert Family Foundation, Detroit, MI, USA.

ORCID-Profile: Kara Anstett, Miranda L McManus, Herb Sarnoff, Jeremie Vitte, Deeann Wallis

Förderung

  • NCI NIH HHS

Zitieren

APA

Staedtke, V., Anstett, K., Bedwell, D., Giovannini, M., Keeling, K., Kesterson, R., Kim, Y., Korf, B., Leier, A., McManus, M. L., Sarnoff, H., Vitte, J., Walker, J. A., Plotkin, S. R., & Wallis, D. (2024). Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials. https://doi.org/10.1177/17407745231207970

Vancouver

Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, et al. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials. 2024. doi:10.1177/17407745231207970

BibTeX
@article{Staedtke2024,
  author = {Staedtke, Verena and Anstett, Kara and Bedwell, David and Giovannini, Marco and Keeling, Kim and Kesterson, Robert and Kim, YooRi and Korf, Bruce and Leier, André and McManus, Miranda L and Sarnoff, Herb and Vitte, Jeremie and Walker, James A and Plotkin, Scott R and Wallis, Deeann},
  title = {Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials},
  journal = {Clinical Trials},
  year = {2024},
  doi = {10.1177/17407745231207970}
}
Kostenlos starten →